MDCO-216 is a complex of dimeric ApoA-IMilano and palmitoyl oleoyl phosphatidylcholine (POPC), previously shown to reduce atherosclerotic plaque burden. Here we studied the effect of incubation of human plasma or serum with MDCO-216 on cholesterol efflux capacity from J774 cells, on prebeta-1 high density lipoprotein (prebeta-1 HDL) and on HDL size assessed by proton nuclear magnetic resonance ...

AIMS Apolipoprotein A-1 (ApoA-1), based on epidemiology, is inversely associated with cardiovascular (CV) events. Human carriers of the ApoA-1 Milano variant have a reduced incidence of CV disease. Regression of atherosclerotic plaque burden was previously observed on intravascular ultrasound (IVUS) with ETC-216, a predecessor of MDCO-216. MDCO-216, a complex of dimeric ApoA-1 Milano and 1-palm...

Expression and secretion of apolipoprotein A-I (apoA-I) by cultured liver cells can be markedly stimulated by triazolodiazepines (TZDs). It has been shown previously that the thieno-TZD Ro 11-1464 increases plasma levels of apoA-I and in vivomacrophage reverse cholesterol transport in mice. However, these effects were only seen at high doses, at which the compound could act on central benzodiaz...

We have designed and implemented a flexible programmable multi-channel digitally-controlled oscillator (MDCO) on an Altera MAX9400 Complex Programmable Logic Device (CPLD) chip. Based on elaborate experiments with the system, we have developed techniques by which to improve its linearity, resolution and stability in an improved MDCO design. This new architecture is programmable to oscillate fro...

OBJECTIVE To determine effects of single ascending doses of MDCO-216 on high-density lipoprotein (HDL) subfractions in relation to changes in cholesterol efflux capacity in healthy volunteers and in patients with stable angina pectoris. APPROACH AND RESULTS Doses of 5- (in volunteers only), 10-, 20-, 30-, and 40-mg/kg MDCO-216 were infused during 2 hours, and plasma and serum were collected d...

HDL delipidation, whole HDL particle infusion with CER-001, MDCO-216, or CSL-112, and gene therapy using HDL-related proteins such as Apo A-I. Further clinical evaluation of direct infusion of mutant (Apo A-1 Milano) or wild-type Apo A-1, linked with a phospholipid carrier, appears warranted since their vascular benefits have been repeatedly demonstrated in animal models and small clinical stud...